Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stock Watcher's Thread / Pix of the Week (POW) -- Ignore unavailable to you. Want to Upgrade?

To: Stock Watcher who wrote (3413)	2/25/1999 10:58:00 AM
From: Jetta	Read Replies (1) \| Respond to of 52051

ITNF-Internet Infinity, splits for shareholders today Monday February 8, 7:27 am Eastern Time Company Press Release Internet Infinity, Inc. Announces 2 for 1 Stock Split! COSTA MESA, Calif.--(BUSINESS WIRE)--Feb. 8, 1999--Internet Infinity, Inc. (OTC BB:ITNF) has announced a 2 for 1 stock split for shareholders of record as of Feb. 25, 1999. George Morris, the chairman, announced today that ''The company believes that splitting shares at this time will give the company expanded support in the securities market and could limit current shareholder dilution from the proposed acquisition of both programs and other companies creating and distributing programs.'' ''We are currently seeking acquisitions for the company to expand the concept for electronic delivery of success programs via the Internet, beyond the current Personal Selling concept. Our Success site design is under way, and we believe the delivery of our own content via the Internet will be available to the company with 60 days,'' Morris continued. Our focus on electronic programming and publishing with delivery of media on the Internet along with delivering CDs and video via our Electronic Media Central subsidiary will help clients and affiliates gain multimedia exposure. Internet Infinity, Inc. is a Costa Mesa company that provides a bundle of e-commerce financial, direct marketing and communication services through the Internet, CD, video tape and television. The company's mission is: ''Support affiliates and clients with multimedia promotion, financial and transactional services to facilitate successful trade on the Internet.'' The primary financial goal for the company is to build shareholder value. Certain information above may be forward-looking statements that involve risks and uncertainties. In such instances, actual results could differ materially due to different factors, including competitive developments and risk factors listed periodically in company reports. IPR02089 Call 800/843-3606, fax 310/374-4984 or e-mail to investor@internetinfinity.com to be added to Press Release list. -------------------------------------------------------------------------------- Contact: Media Promotion, Inc. 310/374-0052 or Internet Infinity, Inc. George Morris, 800/843-3606 georgemorris@internetinfinity.com

To: Stock Watcher who wrote (3413)	2/25/1999 12:23:00 PM
From: blake roberts	Read Replies (2) \| Respond to of 52051

YONKERS, N.Y.--(BW HealthWire)--Feb. 25, 1999--Advanced Viral Research Corp. (OTC BB:ADVR) announced Thursday that its scientists have discovered that its lead antiviral drug, Reticulose, inhibited the production of a key cellular receptor for HIV. Using CD4 positive T-lymphocytes, the scientists found that Reticulose markedly decreased the number of cellular CCR5 receptors. The CCR5 receptor is one of the three most important cell receptors needed by the AIDS virus, HIV, to attach to its target cells and initiate infection. Interference with the function of the CCR5 cellular chemokine receptor is known to increase the resistance of T-lymphocytes and macrophages to HIV infection. A mutation in the CCR5 gene, especially prevalent in individuals of northern European descent, appears to render these individuals resistant to infection by HIV. Commenting on this research, Dr. Shalom Z. Hirschman, president and CEO of Advanced Viral Research Corp., stated: ''The exciting discovery by our scientists that the immunomodulator, Reticulose, interferes with the production of the CCR5 receptor, offers a novel approach to the development of therapeutic agents for HIV infection. This new finding may account, in part, for the beneficial effects of Reticulose in the treatment of HIV infected individuals observed in preliminary clinical trials. Furthermore, this new pathway of inhibiting HIV infection suggests that combination therapy with Reticulose may enhance the therapeutic effectiveness of the AIDS cocktails currently in use.'' Reticulose is a peptide nucleic acid preparation produced by Advanced Viral Research Corp., which, based on previous history, has been shown to be effective against a number of viral diseases. For further information, contact Mark Amster at 954/458-7636. NOTE: This news release contains forward-looking statements that involve risks and uncertainties, including risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by ADVR. RETICULOSE is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries.